Dear Editor,
Spontaneous Pneumothorax (PTX) has received increasing attention as a complication of Coronavirus disease 2019 (COVID-19).1 , 2 In the January article, Ekanem et al. identified PTX in 1.4% of 1619 COVID-19 who had no evidence of trauma during hospitalization.3 Here, we describe our tertiary care center's experience with spontaneous PTX and pneumomediastinum (PTM) among patients hospitalized from March to October 2020 with laboratory confirmed COVID-19 in suburban New York. PTX and/or PTM cases were categorized as either spontaneous (primary or secondary) or as other events (present in close temporal association with trauma or a medical procedure) using prior definitions.4 Outcomes were PTX/PTM events, radiological resolution, recurrence, and overall mortality. During the study period, PTX and/or PTM was documented in 25/1260 (2%) of all hospitalized adult patients with COVID-19.
Ten of twenty-five patients had spontaneous PTX, 1/25 had spontaneous PTM and 7/25 had spontaneous PTX and PTM. In the remaining 7/25 patients, PTX/PTM occurred in close temporal relation to: a medical procedure (3/7), blunt trauma (2/7), a stab wound to the chest (1/7) and intubation (1/7). The mean duration from COVID-19 symptoms to PTX/PTM was 16 (0–46) days. Mechanical ventilation preceded PTX/PTM in 18/25 (72%) of patients by a mean of 9 (0–33) days. A low tidal volume ventilation strategy (4–8 mL/kg) was utilized for all except one study patient. Of the study patients, 52% died (13/25) at a mean of 17 (0–61) days after PTX/PTM. Two patients died shortly after development of tension PTX. The mean duration of hospital stay was 31 (2–104) days. Further details are available in the Table 1 .
Table 1.
Clinical Course and Charactersitics of Patients Hospitalized with COVID-19 and Pneumothorax and/or Pneumomediastinum
| Characteristics of Patients | Number, Percent |
|---|---|
| Patients Hospitalized with COVID-19 (March 2020 – October 2020) | Total n = 1260 |
| Pneumothorax / Pneumomediastinum | |
| Total events | 25/1260 (1.98%) |
| Spontaneous events | 18/1260 = (1.4%) |
| Hospital Course | |
| All-Cause Mortality | 13/25 (52%) |
| Length of Stay; (mean/days, range) | 31 (2–104) |
| Demographics | |
| Age (mean/years) | 55 (23–83) |
| Sex (Male) | 19/25 (76%) |
| Body Mass Index (Mean, range) | 30 (20–48) |
| Chronic Medical Conditions | |
| None | 8/25 (32%) |
| Cardiovascular Disease | 7/25 (28%) |
| Chronic Lung Disease | 1/25 (4%) |
| Imaging Findings at Presentation | |
| Clear Chest X-ray or Computed Tomography | 2/25 (8%) |
| Bilateral Airspace Opacities | 17/25 (68%) |
| Chronic lung disease | 1/25 (4%) |
| Events and Type | |
| Type of Event | |
| Spontaneous PTX | 10/25 (40%) |
| Spontaneous PTM | 1/25 (4%) |
| Spontaneous PTX and PTM | 7/25 (28%) |
| Other (Events with Preceding Factors) | 7/25 (28%) |
| Medical procedure(s) | 3/7 (43%) |
| Intubation | 1/7 (14%) |
| Blunt Trauma | 2/7 (29%) |
| Sharp Trauma | 1/7 (14%) |
| Management | |
| Chest Tube | 15/25 (60%) |
| Resolution | 21/25 (84%) |
| Recurrence | 7/23 (30%) |
This study adds importantly to the growing literature describing pulmonary complications of COVID-19. In our cohort, the overall rate of spontaneous PTX and/or PTM was 1.4% with the majority of patients being male (76%) and having no prior history of lung disease. These findings are remarkably consistent with those of Ekanum et al., who documented a spontaneous PTX rate of 1.4% with a strong male predominance.3 In addition, we found that PTX/PTM reoccurred in around one-third of patients. The overall mortality in this cohort was 52%, while mortality was 36% in Ekanum. However, their study concluded with 4 patients remaining on mechanical ventilation or extracorporeal membrane oxygenation.
The work of Ekanum et al. and our findings indicate that COVID-19 patients are at potential risk for the development of PTX/PTM through a variety of mechanisms. Histological findings from lung tissue in patients with COVID-19 include alveolar damage with septa disruption, desquamation, edema, and exudates with fibrotic/thickened interstitial tissue.5 This tissue damage along with other inflammatory sequelae of COVID-19 likely permits air entry into the pleural and/or mediastinal spaces causing PTX/PTM and also sets the stage for potential recurrence. In addition, COVID-19 patients frequently require mechanical ventilation and/or invasive procedures/interventions under challenging circumstances. In Ekanum, 41% of patients were on mechanical ventilation when PTX developed and in our cohort mechanical ventilation preceded PTX/PTM in nearly three-fourths of patients.
Care of critically patients with COVID-19 is uniquely challenging due to reduced direct patient/provider contact and difficulties in transporting patients for procedures/tests. These factors may contribute to higher than usual risks of procedural complications or delays in diagnosis. Furthermore, a sudden deterioration in respiratory status of the mechanically ventilated COVID-19 patient could be attributed to progression of viral disease, pulmonary embolism, aspiration event, new or worsening ARDS or secondary bacterial infection in addition to PTX/PTM. As such, diagnosis of PTX and PTM in these patients requires a high index of clinical suspicion. Future studies designed to identify more effective ways to prevent PTX and PTM in hospitalized patients with COVID-19 are warranted.
Footnotes
There was no funding for this submission.
Conflict of interest: All authors have no conflicts to disclose
Author contribution: All authors contributed towards conception, data collections and writing the manuscript. DG is the guarantor of the paper and takes responsibility for its integrity.
References
- 1.Martinelli A.W., Ingle T., Newman J., et al. COVID-19 and pneumothorax: a multicentre retrospective case series. Eur Respir J. 2020;56(5) doi: 10.1183/13993003.02697-2020. Print 2020 Nov. doi: 2002697 [pii] [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Wang D., Hu B., Hu C., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, china. JAMA. 2020 doi: 10.1001/jama.2020.1585. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Ekanem E., Podder S., Donthi N., Khandhar S., Mahajan A., Desai M. Spontaneous pneumothorax: an emerging complication of COVID-19 pneumonia. Heart Lung: J Acute Crit Care. January 29, 2021 doi: 10.1016/j.hrtlng.2021.01.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Zarogoulidis P., Kioumis I., Pitsiou G., et al. Pneumothorax: from definition to diagnosis and treatment. J Thorac Dis. 2014;6(Suppl 4):S372–S376. doi: 10.3978/j.issn.2072-1439.2014.09.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Aiolfi A., Bruni B., Biraghi T., et al. Late histological findings in symptomatic COVID-19 patients: a case report. Medicine (Baltimore) 2020;99(28):e21046. doi: 10.1097/MD.0000000000021046. [DOI] [PMC free article] [PubMed] [Google Scholar]